For the year ending 2025-12-31, NRXPW had $6,354K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -28,622 |
| Depreciation and amortization expense | 70 |
| Amortization of operating right of use assets | 73 |
| Stock-based compensation | 228 |
| Provision (recovery) for expected credit losses | 40 |
| Common stock issued in exchange for services | 601 |
| Change in fair value of warrant liabilities | 4,926 |
| Change in fair value of convertible promissory notes | 3,939 |
| Loss on convertible note conversions | -6,201 |
| Gain on exercise of warrant liabilities | 5,369 |
| Loss on issuance of registered direct common stock | -730 |
| Loss on debt settlement | -1,277 |
| Loss on equity method investments | -35 |
| Expense for debt issuance costs due to fair value election on anson notes | 350 |
| Warrant issuance costs related to alvogen termination | 0 |
| Convertible note default penalty | 0 |
| Prepaid expense and other assets | -865 |
| Account receivable | -48 |
| Accounts payable | 113 |
| Operating lease liabilities | -118 |
| Accrued expense and other liabilities | 501 |
| Net cash used in operating activities | -14,112 |
| Business acquisition, net of cash acquired | 2,378 |
| Cash used in investments | 432 |
| Net cash used in investing activities | -2,810 |
| Repayment of convertible note | 0 |
| Repayment of insurance note | 548 |
| Expense for debt issuance costs due to fair value election on anson notes | 350 |
| Proceeds from issuance of insurance loan | 227 |
| Proceeds from anson convertible note, net | 5,000 |
| Proceeds from liability classified warrants | 3,087 |
| Atm offering, net of offering costs | 6,392 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Consideration Warrants | 9,468 |
| Proceeds from issuance of common stock and warrants, net of issuance costs-Warrants Other Than Consideration Warrants | 0 |
| Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs | 0 |
| Net cash provided by financing activities | 23,276 |
| Net increase (decrease) in cash and cash equivalents | 6,354 |
| Cash and cash equivalents at beginning of year | 1,443 |
| Cash and cash equivalents at end of year | 7,797 |
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)